BUZZ-ImmunityBio rises as biotech secures $100 mln to fund global expansion

Reuters03-31

** Shares of biotech firm ImmunityBio IBRX.O rise 2.2% to $6.81 premarket

** Co says it secured $100 million in new financing to support international expansion and drug development

** $75 million is non-dilutive funding from Oberland Capital under an existing deal; royalty payback rate rises modestly, cap unchanged – IBRX

** Separate $25 million of debt converted into ~4.6 million common shares by Nant Capital, cutting overall debt – IBRX

** Co says funds to help expand sales of Anktiva, a cancer immunotherapy for a type of bladder cancer, approved or authorized in ~34 countries

** Shares down ~23% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623586893?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 19:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623586893","market":"nz","top_or_hot":-1,"title":"BUZZ-ImmunityBio rises as biotech secures $100 mln to fund global expansion","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-ImmunityBio rises as biotech secures $100 mln to fund global expansion</title></head><body><p>** Shares of biotech firm ImmunityBio <span>IBRX.O</span> rise 2.2% to $6.81 premarket</p><p>** Co says it secured $100 million in new financing to support international expansion and drug development</p><p>** $75 million is non-dilutive funding from Oberland Capital under an existing deal; royalty payback rate rises modestly, cap unchanged – IBRX</p><p>** Separate $25 million of debt converted into ~4.6 million common shares by Nant Capital, cutting overall debt – IBRX</p><p>** Co says funds to help expand sales of Anktiva, a cancer immunotherapy for a type of bladder cancer, approved or authorized in ~34 countries </p><p>** Shares down ~23% in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-ImmunityBio rises as biotech secures $100 mln to fund global expansion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-ImmunityBio rises as biotech secures $100 mln to fund global expansion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-31 19:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-ImmunityBio rises as biotech secures $100 mln to fund global expansion</title></head><body><p>** Shares of biotech firm ImmunityBio <span>IBRX.O</span> rise 2.2% to $6.81 premarket</p><p>** Co says it secured $100 million in new financing to support international expansion and drug development</p><p>** $75 million is non-dilutive funding from Oberland Capital under an existing deal; royalty payback rate rises modestly, cap unchanged – IBRX</p><p>** Separate $25 million of debt converted into ~4.6 million common shares by Nant Capital, cutting overall debt – IBRX</p><p>** Co says funds to help expand sales of Anktiva, a cancer immunotherapy for a type of bladder cancer, approved or authorized in ~34 countries </p><p>** Shares down ~23% in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL4N40J11B:1","article_id":"2623586893","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623586893","pubTimestamp":1774957495,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-ImmunityBio rises as biotech secures $100 mln to fund global expansion** Shares of biotech firm ImmunityBio IBRX.O rise 2.2% to $6.81 premarket** Co says it secured $100 million in new financing to support international expansion and drug development** $75 million is non-dilutive funding from Oberland Capital under an existing deal; royalty payback rate rises modestly, cap unchanged – IBRX** Separate $25 million of debt converted into ~4.6 million common shares by Nant Capital, cutting overall debt – IBRX** Co says funds to help expand sales of Anktiva, a cancer immunotherapy for a type of bladder cancer, approved or authorized in ~34 countries ** Shares down ~23% in 2025  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IBRX":"ImmunityBio, Inc."},"translate_title":"BUZZ-ImmunityBio股价上涨，biotech获得1亿美元资助全球扩张","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"BUZZ-ImmunityBio rises as biotech secures $100 mln to fund global expansion** Shares of biotech firm ImmunityBio IBRX.O rise 2.2% to $6.81 premarket** Co says it secured $100 million in new financing to support international expansion and drug development** $75 million is non-dilutive funding from Oberland Capital under an existing deal; royalty payback rate rises modestly, cap unchanged – IBRX** Separate $25 million of debt converted into ~4.6 million common shares by Nant Capital, cutting overall debt – IBRX** Co says funds to help expand sales of Anktiva, a cancer immunotherapy for a type of bladder cancer, approved or authorized in ~34 countries ** Shares down ~23% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623586893","isCrawlerRequest":true}